Entities / Company
Aurinia (Canada).
company in Victoria, Canada
- Reports this week
- 0
- Active events
- 0
- Connections
- 18
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Zacks Investment Research provided stock analysis and rankings for Aurinia, noting Kevin Matras's executive role.Some support9 reports
-
Greg Keenan was appointed Chief Medical Officer of Aurinia on June 30, 2025.Speculative1 report
-
Aurinia, a company, is based in Edmonton.Some support1 report
-
Aurinia shares underperformed the S&P 500 gain in late July 2025.Some support1 report
-
Aurinia (Canada)'s CMO justified the use of a 24-week dosing schedule for its treatment.Some support1 report
-
Aurinia (Canada) received a Zacks upgrade driven by an upward trend in its earnings estimates.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Aurinia (Canada) this week
News at the entities that move Aurinia (Canada) most-
FDA Mentioned togetherGeneric medicine services are seeking approval for launch from the FDA.Moves Aurinia (Canada)
Connections
The 1 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Mentioned together
The provided evidence does not describe a direct relationship or coupling between Aurinia and the FDA.
History
Events by the month they beganJune 2026
7 events- Aurinia's LUPKYNIS received FDA approval on July 31, 2025.
- Zacks Investment Research provided stock analysis and rankings for Aurinia, noting Kevin Matras's executive role.
- Greg Keenan was appointed Chief Medical Officer of Aurinia on June 30, 2025.
- Aurinia, a company, is based in Edmonton.
- Aurinia shares underperformed the S&P 500 gain in late July 2025.
- Aurinia (Canada)'s CMO justified the use of a 24-week dosing schedule for its treatment.
- Aurinia (Canada) received a Zacks upgrade driven by an upward trend in its earnings estimates.